Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)

Gastroesophageal carcinomas, including gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC), pose a global health challenge due to their heterogeneity. The approach to diagnosis and treatment should first differentiate between GEA and ESCC. Over the past decade, therap...

ver descrição completa

Detalhes bibliográficos
Autores: Alsina Maqueda, Maria, Teijo Quintáns, Ana, Cuatrecasas, Miriam, Fernández Aceñero, María Jesús, Fernández Montes, Ana, Gómez Martín, Carlos, Jiménez Fonseca, Paula, Martínez Ciarpaglini, Carolina, Rivera Herrero, Fernando, Iglesias Coma, Mar
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2025
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositório:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:dnet:recercat____::b630c5ba6402815dfc8697ef4802a492
Acesso em linha:https://hdl.handle.net/10230/73171
http://dx.doi.org/10.1007/s12094-025-03865-6
Access Level:Acceso aberto
Palavra-chave:Biomarkers
Claudin 18.2
Gastroesophageal carcinoma
HER2
MSI/dMMR
PD-L1
Descrição
Resumo:Gastroesophageal carcinomas, including gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC), pose a global health challenge due to their heterogeneity. The approach to diagnosis and treatment should first differentiate between GEA and ESCC. Over the past decade, therapies for metastatic or advanced GEA/ESCC have expanded, with several new therapeutic targets alongside trastuzumab for metastatic HER2-positive GEA. Four key biomarkers are essential for targeted therapy: HER2 overexpression/amplification, deficient mismatch repair/microsatellite instability (dMMR/MSI), PD-L1, and Claudin18.2 expression. Immunohistochemistry is the recommended method for these biomarkers evaluation. In addition, the assessment of biomarkers like FGFR2b is likely to become routine in the near future. Experts from the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) have formed a consensus to optimize biomarker detection and usage in clinical practice. Their recommendations aim to improve personalized treatment strategies for GEA and ESCC patients, integrating new diagnostic insights into routine care.

Registros relacionados